Results 161 to 170 of about 407,552 (296)

Machine learning model for intravenous immunoglobulin resistance in Kawasaki disease: model development and validation study. [PDF]

World J Pediatr
Zhang JY, You TJ, Li J, Dong JF, Xu L, Li X, Hu JL, Tang YJ, Hou M, Liu Y, Xu ZX, Lv HT, Huang HB.   +12 more
europepmc   +1 more source

Reframing the Gut–Brain Axis: The Gut Wall as a Neural Immune Interface in Multiple Sclerosis and Autoimmune Neurological Diseases

Annals of Neurology, EarlyView.
Gut wall physiology in multiple sclerosis (MS) and autoimmune neurologic diseases remains underexplored but may span gut barrier dysfunction, enteric glial targeting, mucosal immune dysregulation, and autoimmune targets within the enteric nervous system (ENS).
Federico Montini, Sean J. Pittock, Laura Cacciaguerra, Howard L. Weiner, Luke A. Schwerdtfeger   +4 more
wiley   +1 more source

Predictors of Intravenous Immunoglobulin Non-Responsiveness in Children With Kawasaki Disease. [PDF]

Immun Inflamm Dis
Cheng Y, Chen B.
europepmc   +1 more source

Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barré syndrome: a retrospective study. [PDF]

Front Immunol
Liu C, Wang K, Zhang S, Gao N, Xu G, Qi F.   +5 more
europepmc   +1 more source

Intravenous immunoglobulins. [PDF]

BMJ, 1991
openaire   +2 more sources

Efficacy of intravenous immunoglobulin in children with drug-resistant epilepsy. [PDF]

Front Neurol
Ebdalla A, Scantlebury MH, Appendino JP, Ho A, Jacobs J.   +4 more
europepmc   +1 more source

Multimodal Echocardiographic Assessment in Intravenous Immunoglobulin-Resistant Kawasaki Disease: From Prediction to Long-Term Surveillance. [PDF]

Echocardiography
Xu X, Wu T, Wei K.
europepmc   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Reappraising the role of procalcitonin in predicting intravenous immunoglobulin resistance in Kawasaki disease. [PDF]

Ann Pediatr Cardiol
Kundavaram R, Kumar A.
europepmc   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source